Wall Street Analysts See a 31.3 percent Upside in Adma Biologics Can the Stock Really Move This High?

ADMA Stock  USD 21.18  0.12  0.56%   
About 57% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
  
The average of price targets set by Wall Street analysts indicates a potential upside of 31.3 percent in Adma Biologics . While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read at zacks.com
zacks News
  

ADMA Biologics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ADMA Biologics Fundamental Analysis

We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

ADMA Biologics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

ADMA Biologics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.

Peers

ADMA Biologics Related Equities

CDTXCidara Therapeutics   16.91   
0%
100.0%
SANASana Biotechnology   11.06   
0%
65.0%
FATEFate Therapeutics   10.63   
0%
62.0%
ANTXAN2 Therapeutics   8.94   
0%
52.0%
ATRAAtara Biotherapeutics   8.11   
0%
47.0%
IBIOIbio   7.76   
0%
45.0%
MDGLMadrigal Pharmaceuticals   5.53   
0%
32.0%
MCRBSeres Therapeutics   5.48   
0%
32.0%
ETNB89bio   4.53   
0%
26.0%
ACLXArcellx   3.69   
0%
21.0%
AKBAAkebia Ther   3.30   
0%
19.0%
RCUSArcus Biosciences   2.94   
0%
17.0%
INMBINmune Bio   2.31   
0%
13.0%
CRBUCaribou Biosciences   2.02   
0%
11.0%
PLXProtalix Biotherapeutics   1.81   
0%
10.0%
BCRXBioCryst Pharmaceuticals   1.47   
0%
8.0%
STOKStoke Therapeutics   1.42   
0%
8.0%
PLRXPliant Therapeutics   1.01   
0%
5.0%
VXRTVaxart   1.64   
9.0%
0%
ANEBAnebulo Pharmaceuticals   2.67   
15.0%
0%
TFFPTff Pharmaceuticals   2.86   
16.0%
0%
TNXPTonix Pharmaceuticals   5.00   
29.0%
0%
XFORX4 Pharmaceuticals   8.11   
47.0%
0%

Complementary Tools for ADMA Stock analysis

When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device